These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21824151)

  • 21. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser.
    Park KK; Swan J; Koo J
    Dermatol Online J; 2012 Mar; 18(3):2. PubMed ID: 22483513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
    Girolomoni G; Abeni D
    Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with the systemic treatment of severe forms of psoriasis.
    Tichý M; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Mar; 156(1):29-40. PubMed ID: 22580858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
    Farnsworth NN; George SJ; Hsu S
    Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
    [No Abstract]   [Full Text] [Related]  

  • 34. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
    Alsharqi A; Parslew R; Dever B; Arslanian V
    Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis.
    Piaserico S; Sandini E; Saldan A; Abate D
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S73-6. PubMed ID: 25381985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCP-1 in psoriatic patients: effect of biological therapy.
    Lembo S; Capasso R; Balato A; Cirillo T; Flora F; Zappia V; Balato N; Ingrosso D; Ayala F
    J Dermatolog Treat; 2014 Feb; 25(1):83-6. PubMed ID: 23480385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxyradical-mediated clastogenic plasma factors in psoriasis: increase in clastogenic activity after PUVA.
    Filipe P; Emerit I; Alaoui Youssefi A; Levy A; Cernjavski L; Freitas J; de Castro JL
    Photochem Photobiol; 1997 Oct; 66(4):497-501. PubMed ID: 9337621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis.
    Bosè F; Petti L; Diani M; Moscheni C; Molteni S; Altomare A; Rossi RL; Talarico D; Fontana R; Russo V; Altomare G; Reali E
    Am J Pathol; 2013 Aug; 183(2):413-21. PubMed ID: 23731727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viewpoint on handling anti-TNF failure in psoriasis.
    Bracke S; Lambert J
    Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy.
    Pivarcsi A; Meisgen F; Xu N; Ståhle M; Sonkoly E
    Br J Dermatol; 2013 Sep; 169(3):563-70. PubMed ID: 23600954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.